This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Liraglutide Efficacy on Glucocorticoid Induced Hyperglycemia in Patients High Risk for Diabetes

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2013 by Amit Tirosh, Rabin Medical Center.
Recruitment status was:  Not yet recruiting
Information provided by (Responsible Party):
Amit Tirosh, Rabin Medical Center Identifier:
First received: December 15, 2013
Last updated: December 22, 2013
Last verified: December 2013
Glucocorticoids therapy exposes the patient to an increased risk for diabetes morbidity. However, there is no proven preventive therapy. GLP-1-RA has shown to improve glucose metabolism in healthy volunteers treated with glucocorticoids. We assume that GLP-1-RA will improve glucose metabolism in patients with high risk for diabetes morbidity, treated with glucocorticoids.

Condition Intervention Phase
Glucocorticoid Induced Hyperglycemia Drug: Liraglutide Drug: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention

Resource links provided by NLM:

Further study details as provided by Amit Tirosh, Rabin Medical Center:

Primary Outcome Measures:
  • Glucose levels 2 hours after 75 gr OGTT [ Time Frame: 6 weeks ]

Estimated Enrollment: 36
Study Start Date: January 2014
Estimated Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo Drug: Placebo
Active Comparator: Intervention
Liraglutide, tapered from 0.6 mg/day to 1.8 mg/day.
Drug: Liraglutide


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Planned treatment with T. Prednisone in dosage >0.5 mg/kg for two weeks or more.
  • Age >18 years
  • Body mass index >27 kg/m2 OR 1st degree relative with type 2 diabetes mellitus OR hypertension OR hyperlipidemia OR gestational diabetes in the past OR diagnosis of polycystic ovary syndrome.

Exclusion criteria:

  • Glycosylated hemoglobin A1c >6.5%
  • Diagnosis of diabetes mellitus or treatment with anti-glycemic drug
  • Pancreatitis (acute or chronic) in the past
  • Active malignancy
  • Medullary thyroid carcinoma or multiple endocrine neoplasm type 2 of the patient or of 1st degree relative
  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02016846

Contact: Amit Tirosh, MD +972.50.8191078

Rabin Medical Center, Beilinson Campus Not yet recruiting
Petah Tiqva, Israel
Contact: Amit Tirosh, MD   
Sponsors and Collaborators
Rabin Medical Center
  More Information

Responsible Party: Amit Tirosh, Dr, Rabin Medical Center Identifier: NCT02016846     History of Changes
Other Study ID Numbers: 0209-13
Study First Received: December 15, 2013
Last Updated: December 22, 2013

Additional relevant MeSH terms:
Glucose Metabolism Disorders
Metabolic Diseases
Hypoglycemic Agents
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists processed this record on September 21, 2017